American Society of Hirudotherapy

Heparin-induced thrombocytopenia: a general review

Review published in J Infus Nurs (2007)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Narrative reviewDrug DevelopmentClinical LiteratureSwanson JM · Journal of infusion nursing, 2007

Abstract

Unfractionated heparin is widely used for numerous clinical situations. A well-known adverse effect of heparin exposure is thrombocytopenia. Heparin-induced thrombocytopenia is a clinicopathologic syndrome that can be associated with severe complications and significant mortality. The pathophysiology of heparin-induced thrombocytopenia includes an immune-mediated reaction to heparin that activates platelets and results in an acquired hypercoagulability. Diagnosis of heparin-induced thrombocytopenia should incorporate clinical signs and symptoms and laboratory testing for heparin-induced thrombocytopenia antibodies. Therapy should include discontinuation of heparin, initiation of a direct thrombin inhibitor, and eventually therapy with warfarin (only after the platelet count is at least 100 x 10(9)/L).

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsArginineDrug MonitoringFactor Xa InhibitorsFondaparinuxHeparinHirudinsHumansNursing AssessmentPeptide FragmentsPipecolic AcidsPlatelet ActivationPlatelet CountPolysaccharidesRecombinant ProteinsRisk FactorsSulfonamidesThrombinThrombocytopeniaTime FactorsTreatment OutcomeWarfarin

Summary

This review describes the immune-mediated pathophysiology of heparin-induced thrombocytopenia, recommends diagnosis via clinical signs and antibody testing, and outlines therapy with heparin discontinuation, a direct thrombin inhibitor, and delayed warfarin until platelet count reaches at least 100 x 10(9)/L.

Why This Matters for Hirudotherapy

This general review covers heparin-induced thrombocytopenia as a clinicopathologic syndrome, describing its immune-mediated pathophysiology, the importance of combining clinical assessment with laboratory antibody testing for diagnosis, and a treatment algorithm of heparin discontinuation, initiation of a direct thrombin inhibitor, and eventual warfarin transition only after platelet recovery to at least 100 × 10⁹/L. The abstract refers generically to direct thrombin inhibitors without naming lepirudin, hirudin, or any specific agent, and does not mention leeches or the leech secretome. Therefore, no specific relevance to hirudotherapy can be established from the abstract text, and the connection is at most indirect. The abstract provides no primary data and no hirudin-specific pharmacology or outcomes.

Citation

Reference (Vancouver style)

Swanson JM. Heparin-induced thrombocytopenia: a general review. J Infus Nurs. 2007;30(4):232-240. doi:10.1097/01.NAN.0000281533.04808.54. PMID: 17667079

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.